Atigliflozin

Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus[1].

Product Specifications

CAS Number

[647834-15-9]

Product Name Alternative

AVE-2268

UNSPSC

12352005

Target

SGLT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/atigliflozin.html

Solubility

10 mM in DMSO

Smiles

O[C@H]1[C@H](OC2=C(CC3=CC=C(OC)C=C3)SC=C2)O[C@H](CO)[C@@H](O)[C@@H]1O

Molecular Formula

C18H22O7S

Molecular Weight

382.43

References & Citations

[1]Schudok M, et al. The magic of small structure differences in a sodium-glucose cotransporter drug discovery project-14 C-labelled drug candidates in a key-differentiating study. J Labelled Comp Radiopharm. 2021 Feb;64 (2) :73-76.|[2]Bickel M, et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58 (11) :574-80.